Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer

Cited by (1,017)

Items 601–700 of 1,017

1. Clinical Outcomes in Non-Small-Cell Lung Cancer Patients Receiving Concurrent Metformin and Immune Checkpoint Inhibitors
   Muhammad Zubair Afzal, Konstantin H. Dragnev, Tayyaba Sarwar, Keisuke Shirai · 2019 · Lung Cancer Management
2. Pembrolizumab plus Chemotherapy in Lung Cancer
   Manuel D Gil-Sierra, Silvia Fenix-Caballero, Emilio Jesús Alegre Del Rey · 2018 · New England Journal of Medicine
3. A synergistic triad of chemotherapy, immune checkpoint inhibitors, and caloric restriction mimetics eradicates tumors in mice
   Lévesque, Sarah, Le Naour, Julie, Pietrocola, Federico, Paillet, Juliette, Kremer, Margerie, Castoldi, Francesca, Baracco, Elisa E., Wang, Yan, Vacchelli, Erika, Stoll, Gautier et al. · 2019 · OncoImmunology
4. Emerging biomarkers for immune checkpoint inhibition in lung cancer
   George Cyriac, Leena Gandhi · 2018 · Seminars in Cancer Biology
5. Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes
   Alessio Cortellini, Alex Friedlaender, Giuseppe Luigi Banna, Giampiero Porzio, Melissa Bersanelli, Federico Cappuzzo, Joachim G.J.V. Aerts, Raffaele Giusti, Emilio Bria, Diego Luigi Cortinovis et al. · 2020 · Clinical Lung Cancer
6. Tumor Immunology and Immunotherapy of Non-Small-Cell Lung Cancer
   Tina Cascone, Jared J. Fradette, Monika Pradhan, Don Lynn Gibbons · 2021 · Cold Spring Harbor Perspectives in Medicine
7. Disorder of Coagulation-Fibrinolysis System: An Emerging Toxicity of Anti-PD-1/PD-L1 Monoclonal Antibodies
   Ryo Sato, Kosuke Imamura, Shinya Sakata, Tokunori Ikeda, Yuko Horio, Shinji Iyama, Kimitaka Akaike, Shohei Hamada, Takayuki Jodai, Kei Nakashima et al. · 2019 · Journal of Clinical Medicine
8. The clinical significance of soluble PD-1 and PD-L1 in lung cancer
   Taher Abu Hejleh, Muhammad Furqan, Zuhair K. Ballas, Gerald H. Clamon · 2019 · Critical Reviews in Oncology/Hematology
9. Smokers or non-smokers: who benefits more from immune checkpoint inhibitors in treatment of malignancies? An up-to-date meta-analysis
   Jiahang Mo, Xiao Hu, Lihu Gu, Bangsheng Chen, Parikshit Asutosh Khadaroo, Zefeng Shen, Lei Dong, Yuqi Lv, Marylin Nyaradzo Chitumba, Jiequan Liu · 2020 · World Journal of Surgical Oncology
10. Immunotherapy in NSCLC patients with brain metastases. Understanding brain tumor microenvironment and dissecting outcomes from immune checkpoint blockade in the clinic
    Noelia Vilariño, Jordi Bruna, Joaquim Bosch‐Barrera, Manuel Valiente, Ernest Nadal · 2020 · Cancer Treatment Reviews
11. Coordination and Redox Dual‐Responsive Mesoporous Organosilica Nanoparticles Amplify Immunogenic Cell Death for Cancer Chemoimmunotherapy
    Fan Zhang, Fangman Chen, Chao Yang, Lei Wang, Hanze Hu, Xuezhao Li, Xiao Zheng, Zheng Wang, Zhimin Chang, Tianyu Li et al. · 2021 · Small
12. Immunotherapy in non-small cell lung cancer: Past, present, and future directions
    Salman Rafi Punekar, Elaine Shum, Cassandra Grello, Sally C. M. Lau, Vamsidhar Velcheti · 2022 · Frontiers in Oncology
13. Modeling Cancer with Flies and Fish
    Ross Leigh Cagan, Leonard Ira Zon, Richard Mark White · 2019 · Developmental Cell
14. Circulating miRNAs and PD-L1 Tumor Expression Are Associated with Survival in Advanced NSCLC Patients Treated with Immunotherapy: a Prospective Study
    Mattia Boeri, Massimo Milione, Claudia Proto, Diego Signorelli, Giuseppe Lo Russo, Carlotta Galeone, Carla Verri, Mavis Mensah, Giovanni Centonze, Antonia Martinetti et al. · 2019 · Clinical Cancer Research
15. Immunotherapy for the First-Line Treatment of Patients with Metastatic Non–Small Cell Lung Cancer
    Pablo Martínez, Solange Peters, Timothy A. Stammers, Jean‐Charles Soria · 2019 · Clinical Cancer Research
16. Advanced-Stage Non–Small Cell Lung Cancer: Advances in Thoracic Oncology 2018
    Jordi Remón, Myung‐Ju Ahn, Nicolas Girard, Melissa Lynne Johnson, Dong‐Wan Kim, Gilberto De Lima Lopes Jr., Rathi Narayana Pillai, Benjamin Solomon, Guillermo Javierre Villacampa, Qing Hua Zhou · 2019 · Journal of Thoracic Oncology
17. Metadherin enhances vulnerability of cancer cells to ferroptosis
    Jianling Bi, Shujie Yang, Li Long, Qun Dai, Nicholas C. Borcherding, Brett Alan Wagner, Garry R. Buettner, Douglas R. Spitz, Kimberly Kay Leslie, Jun Zhang et al. · 2019 · Cell Death and Disease
18. U3-1402 sensitizes HER3-expressing tumors to PD-1 blockade by immune activation
    Koji Haratani, Kimio Yonesaka, Shiki Takamura, Osamu Maenishi, Ryoji Kato, Naoki Takegawa, Hisato Kawakami, Kaoru Tanaka, Hidetoshi Hayashi, Masayuki Takeda et al. · 2019 · Journal of Clinical Investigation
19. Best practices for detection, assessment and management of suspected immune-mediated liver injury caused by immune checkpoint inhibitors during drug development
    Arie Regev, Mark Avigan, Alexandre Kiazand, John Moore Vierling, James H. Lewis, Stephanie O. Omokaro, Adrian M. Di Bisceglie, Robert J. Fontana, Herbert L. Bonkovsky, James W. Freston et al. · 2020 · Journal of Autoimmunity
20. Predictable Clinical Benefits without Evidence of Synergy in Trials of Combination Therapies with Immune-Checkpoint Inhibitors
    Adam Christopher Palmer, Benjamin Izar, Haeun Hwangbo, Peter Karl Sorger · 2022 · Clinical Cancer Research
21. Androgen Signaling Contributes to Sex Differences in Cancer by Inhibiting NF-κB Activation in T Cells and Suppressing Antitumor Immunity
    Xiaomin Zhang, Limin Cheng, Chengqi Gao, Jing Chen, Shuangye Liao, Yongqiang Zheng, Liping Xu, Jingjing He, Danyang Wang, Ziqian Fang et al. · 2023 · Cancer Research
22. Therapy for Stage IV Non–Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2023.3
    Ishmael A. Jaiyesimi, Natasha B. Leighl, Nofisat Ismaila, Krishna Chaitanya Alluri, Narjust Florez, Shirish M. Gadgeel, Gregory A. Masters, Erin Lynn Schenk, Bryan James Schneider, Lecia Van Dam Sequist et al. · 2024 · Journal of Clinical Oncology
23. AXL targeting restores PD-1 blockade sensitivity of STK11/LKB1 mutant NSCLC through expansion of TCF1+ CD8 T cells
    Li, Huiyu, Liu, Zhida, Liu, Longchao, Zhang, Hongyi, Han, Chuanhui, Girard, Luc, Park, Hyunsil, Zhang, Anli, Dong, Chunbo, Ye, Jianfeng et al. · 2022 · Cell Reports Medicine
24. Molecularly guided therapy versus chemotherapy after disease control in unfavourable cancer of unknown primary (CUPISCO): an open-label, randomised, phase 2 study
    Alwin Krämer, Tilmann Bochtler, Chantal Pauli, Kai‐Keen Shiu, Natalie Cook, Juliana Janoski De Menezes, Roberto Pazo-Cid, Ferrán Losa, Debbie G. J. Robbrecht, Jiří Tomášek et al. · 2024 · The Lancet
25. Advances in the management of endometrial cancer
    Bradley R. Corr, Britt Kristina Erickson, Emma Longley Barber, Christine M. Fisher, Brian M. Slomovitz · 2025 · BMJ
26. Pembrolizumab in combination with ipilimumab as second-line or later therapy for advanced non–small-cell lung cancer: KEYNOTE-021 cohorts D and H
    Matthew A. Gubens, Lecia Van Dam Sequist, James P. Stevenson, Steven Francis Powell, Liza Cosca Villaruz, Shirish M. Gadgeel, Corey Jay Langer, Amita Patnaik, Hossein Borghaei, Shadia Ibrahim Jalal et al. · 2018 · Lung Cancer
27. Association of PD‐L1 expression status with the efficacy of PD‐1/PD‐L1 inhibitors and overall survival in solid tumours: A systematic review and meta‐analysis
    Xi Liu, Chang‐Ying Guo, Fangfang Tou, Xiaoming Wen, Yukang Kuang, Qian Zhu, Hao Hu · 2019 · International Journal of Cancer
28. Impact of PD‐L1 expression and human papillomavirus status in anti‐PD1/PDL1 immunotherapy for head and neck squamous cell carcinoma—Systematic review and meta‐analysis
    Jaimin J. Patel, Dylan A. Levy, Shaun A. Nguyen, Hannah M. Knochelmann, Terry A. Day · 2019 · Head & Neck
29. First line Immunotherapy for Non-Small Cell Lung Cancer
    Nicola Joseph Nasser, Miguel Gorenberg, Abed Agbarya · 2020 · Pharmaceuticals
30. Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non–small-cell lung cancer: Phase 1 cohorts from the KEYNOTE-021 study
    Shirish M. Gadgeel, James P. Stevenson, Corey Jay Langer, Leena Gandhi, Hossein Borghaei, Amita Patnaik, Liza Cosca Villaruz, Matthew A. Gubens, Ralph J. Hauke, James Chih‐Hsin Yang et al. · 2018 · Lung Cancer
31. Switching administration of anti‐PD ‐1 and anti‐PD‐L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non‐small cell lung cancer: Case series and literature review
    Shingo Kitagawa, Taiki Hakozaki, Rui Kitadai, Yukio Hosomi · 2020 · Thoracic Cancer
32. Tislelizumab: an investigational anti-PD-1 antibody for the treatment of advanced non-small cell lung cancer (NSCLC)
    Si‐Yang Maggie Liu, Yi-Long Lung Cancer Wu · 2020 · Expert Opinion on Investigational Drugs
33. Continuous monitoring of neutrophils to lymphocytes ratio for estimating the onset, severity, and subsequent prognosis of immune related adverse events
    Ryosuke Matsukane, Hiroyuki Watanabe, Haruna Minami, Kojiro Hata, Kimitaka Suetsugu, Toshikazu Tsuji, Satohiro Masuda, Isamu Okamoto, Takashi Nakagawa, Takamichi Ito et al. · 2021 · Scientific Reports
34. Inhibition of the BTK-IDO-mTOR axis promotes differentiation of monocyte-lineage dendritic cells and enhances anti-tumor T cell immunity
    Madhav D. Sharma, Rafał Pacholczyk, Huidong Shi, Zuzana Berrong, Yousef Zakharia, Austin Greco, Chang-Sheng S. Chang, Sudharshan Eathiraj, Eugene Paul Kennedy, Thomas Cash et al. · 2021 · Immunity
35. The immune modifying effects of chemotherapy and advances in chemo-immunotherapy
    Daniel R. Principe, Suneel Deepak Kamath, Murray Korc, Hidayatullah G. Munshi · 2022 · Pharmacology & Therapeutics
36. Immune Checkpoint Inhibitor Use in Solid Organ Transplant Recipients: A Systematic Review
    Andrew Jay Portuguese, Scott S. Tykodi, Christopher D. Blosser, Ted Gooley, John A. Thompson, Evan Thomas Hall · 2022 · Journal of the National Comprehensive Cancer Network
37. Immunotherapy for small cell lung cancer: mechanisms of resistance
    Gerhard Hamilton, Barbara Rath · 2019 · Expert Opinion on Biological Therapy
38. The landscape of immune checkpoint inhibitor plus chemotherapy versus immunotherapy for advanced non‐small‐cell lung cancer: A systematic review and meta‐analysis
    Chengdi Wang, Wenliang Qiao, Yuting Jiang, Min Zhu, Jun Shao, Tao Wang, Dan Liu, Weimin Li · 2019 · Journal of Cellular Physiology
39. Performance status and end‐of‐life care among adults with non–small cell lung cancer receiving immune checkpoint inhibitors
    Laura A. Petrillo, Areej R El-Jawahri, Ryan David Nipp, Morgan RL Lichtenstein, Sienna Durbin, Kerry Lynn Reynolds, Joseph Andrew Greer, Jennifer S. Temel, Justin F. Gainor · 2020 · Cancer
40. Thyroid Toxicity Following Immune Checkpoint Inhibitor Treatment in Advanced Cancer
    Christopher Alan Muir, Alexander Maxwell Menzies, Roderick John Clifton-Bligh, Venessa Tsang · 2020 · Thyroid
41. Immunotherapy Breakthroughs in the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
    Christian Borel, Alain C. Jung, Mickaël Burgy · 2020 · Cancers
42. The effect of smoking status on efficacy of immune checkpoint inhibitors in metastatic non-small cell lung cancer: A systematic review and meta-analysis
    Linzheng Dai, Bo Jin, Tingting Liu, Jun Chen, Guang Li, Jun Dang · 2021 · EClinicalMedicine
43. Immune-based combination therapy to convert immunologically cold tumors into hot tumors: an update and new insights
    Jiaojiao Ni, Zizhen Zhang, Ming-jie Ge, Jingyu Chen, Wei Zhuo · 2022 · Acta Pharmacologica Sinica
44. Durvalumab With or Without Tremelimumab in Combination With Chemotherapy in First-Line Metastatic NSCLC: Five-Year Overall Survival Outcomes From the Phase 3 POSEIDON Trial
    Solange Peters, Byoung Chul Cho, Alexander Valerievich Luft, Jorge Alatorre-Alexander, Sarayut Lucien Geater, Константин Константинович Лактионов, Dmytro V. Trukhin, Sang‐We Kim, G Ursol, Maen Hussein et al. · 2024 · Journal of Thoracic Oncology
45. Cost-effectiveness of pembrolizumab in combination with chemotherapy versus chemotherapy and pembrolizumab monotherapy in the first-line treatment of squamous non-small-cell lung cancer in the US
    Ralph P. Insinga, David J. Vanness, Josephine Louella Feliciano, Kristel Vandormael, Sory Traoré, Flavia Ejzykowicz, Thomas A. Burke · 2019 · Current Medical Research and Opinion
46. A Phase 1–2 Study of Rovalpituzumab Tesirine in Combination With Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Extensive-Stage SCLC
    Jyoti Dhar Malhotra, Petros G. Nikolinakos, Ticiana A.B. Leal, Jonathan M. Lehman, Daniel Morgensztern, Jyoti D. Patel, John M. Wrangle, Giuseppe Curigliano, Laurent Greillier, Melissa Lynne Johnson et al. · 2021 · Journal of Thoracic Oncology
47. Improving antitumor immunity using antiangiogenic agents: Mechanistic insights, current progress, and clinical challenges
    Shu‐Jin Li, J.Y. Chen, Zhi‐Jun Sun · 2021 · 癌症：英文版
48. Clinical Benefit of First-Line Programmed Death-1 Antibody Plus Chemotherapy in Low Programmed Cell Death Ligand 1–Expressing Esophageal Squamous Cell Carcinoma: A Post Hoc Analysis of JUPITER-06 and Meta-Analysis
    Hao‐Xiang Wu, Yi‐Qian Pan, Ye He, Zixian Wang, Wen‐Long Guan, Yan‐Xing Chen, Yichen Yao, Ning‐Yi Shao, Rui‐Hua Xu, Feng Wang · 2022 · Journal of Clinical Oncology
49. Spatial signatures for predicting immunotherapy outcomes using multi-omics in non-small cell lung cancer
    Thazin Nwe Aung, James H. Monkman, Jonathan Warrell, Ioannis Athanasios Vathiotis, Katherine Bates, Niki Gavrielatou, Ioannis Panagiotis Trontzas, Chin Wee Tan, Aileen I. Fernandez, Myrto K. Moutafi et al. · 2025 · Nature Genetics
50. Integrated analysis of the immunological and genetic status in and across cancer types: impact of mutational signatures beyond tumor mutational burden
    Jan Budczies, Anja Seidel, Petros Christopoulos, Volker Endris, Matthias Kloor, Balázs Győrffy, Barbara Seliger, Peter Schirmacher, Albrecht Stenzinger, Carsten Denkert · 2018 · OncoImmunology
51. Combinatorial Approaches With Checkpoint Inhibitors to Enhance Anti-tumor Immunity
    Barbara Seliger · 2019 · Frontiers in Immunology
52. Histone Deacetylase Inhibition in Non-small Cell Lung Cancer: Hype or Hope?
    Hirva Mansurali Mamdani, Shadia Ibrahim Jalal · 2020 · Frontiers in Cell and Developmental Biology
53. Advances in Pancreatic Ductal Adenocarcinoma Treatment
    Eric M. Anderson, Shant Thomassian, Jun Gong, Andrew Eugene Hendifar, Arsen Osipov · 2021 · Cancers
54. Evolving trends in lung cancer
    Ramakant Deshpand, Manish Chandra, Amit Rauthan · 2022 · Indian Journal of Cancer
55. HIF1α-regulated glycolysis promotes activation-induced cell death and IFN-γ induction in hypoxic T cells
    Hongxing Shen, Oluwagbemiga A. Ojo, Haitao Ding, Logan J. Mullen, Chuan Xing, Mohammed Iqbal Hossain, Abdelrahman Yassin, Vivian Yan Shi, Zach Lewis, Ewa Podgórska et al. · 2024 · Nature Communications
56. Predictive value of oncogenic driver subtype, programmed death‐1 ligand (PD‐L1) score, and smoking status on the efficacy of PD‐1/PD‐L1 inhibitors in patients with oncogene‐driven non–small cell lung cancer
    Terry L. Ng, Yiwei Liu, Anastasios Dimou, Tejas Patil, Dara L. Aisner, Zhengwei Dong, Tao Jiang, Chunxia Su, Chunyan Wu, Shengxiang Ren et al. · 2018 · Cancer
57. Immunotherapy is associated with improved survival and decreased neurologic death after SRS for brain metastases from lung and melanoma primaries
    C.M. Lanier, Ryan T. Hughes, Tamjeed Ahmed, Michael C. LeCompte, Adrianna Henson Masters, William Jeffrey Petty, Jimmy Ruiz, Pierre L. Triozzi, Jing Su, Stacy O’Neill et al. · 2019 · Neuro-Oncology Practice
58. Immune Modulation by Telomerase-Specific Oncolytic Adenovirus Synergistically Enhances Antitumor Efficacy with Anti-PD1 Antibody
    Nobuhiko Kanaya, Shinji Kuroda, Yoshihiko Kakiuchi, Kento Kumon, Tomoko Tsumura, Masashi Hashimoto, Toshiaki Morihiro, Tetsushi Kubota, Katsuyuki Aoyama, Satoru Kikuchi et al. · 2020 · Molecular Therapy
59. First-Line Immune-Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Current Landscape and Future Progress
    Zhangfeng Huang, Wenhao Su, Tong Lu, Yuanyong Wang, Yanting Dong, Yi Qin, Dahai Liu, Lili Sun, Wenjie Jiao · 2020 · Frontiers in Pharmacology
60. Efficacy and Safety of Anti-PD-1 Plus Anlotinib in Patients With Advanced Non–Small-Cell Lung Cancer After Previous Systemic Treatment Failure—A Retrospective Study
    Peiliang Wang, Xiaozhuang Fang, Tianwen Yin, Hairong Tian, Jinming Yu, Feifei Teng · 2021 · Frontiers in Oncology
61. Nephrotoxicity as a Complication of Chemotherapy and Immunotherapy in the Treatment of Colorectal Cancer, Melanoma and Non-Small Cell Lung Cancer
    Joanna Jagieła, Piotr Bartnicki, Jacek Rysz · 2021 · International Journal of Molecular Sciences
62. Changes in Circulating Tumor DNA Reflect Clinical Benefit Across Multiple Studies of Patients With Non–Small-Cell Lung Cancer Treated With Immune Checkpoint Inhibitors
    Diana Merino Vega, Katherine K. Nishimura, Névine M.-D. Zariffa, Jeffrey C. Thompson, Antje Hoering, Vanessa J. Cilento, Adam Rosenthal, Valsamo Anagnostou, Jonathan F. Baden, Julia A. Beaver et al. · 2022 · JCO Precision Oncology
63. spaCI: deciphering spatial cellular communications through adaptive graph model
    Ziyang Tang, Tonglin Zhang, Baijian Yang, Jing Su, Qianqian Song · 2022 · Briefings in Bioinformatics
64. Gut commensal Bifidobacterium-derived extracellular vesicles modulate the therapeutic effects of anti-PD-1 in lung cancer
    Ranjan Preet, Md Atiqul Islam, Jiyoung Shim, Ganeshkumar Rajendran, Amrita Mitra, Vikalp Vishwakarma, Caleb Kutz, Sonali Choudhury, Harsh B. Pathak, Qun Dai et al. · 2025 · Nature Communications
65. Non-small cell lung cancer brain metastases and the immune system: From brain metastases development to treatment
    Elie Rassy, Angela Botticella, Joseph Gergi Kattan, Cecile Le Pechoux, Benjamin Besse, Lizza E.L. Hendriks · 2018 · Cancer Treatment Reviews
66. JASPER: Phase 2 trial of first‐line niraparib plus pembrolizumab in patients with advanced non–small cell lung cancer
    Ramalingam, Suresh S., Thara, Eddie, Awad, Mark M., Dowlati, Afshin, Haque, Basir, Stinchcombe, Thomas E., Dy, Grace K., Spigel, David R., Lu, Sharon, Iyer Singh, Nithya et al. · 2022 · Cancer
67. Treg Destabilization and Reprogramming: Implications for Cancer Immunotherapy
    Munn, David H., Sharma, Madhav D., Johnson, Theodore S. · 2018 · Cancer Research
68. Impact of early inflammatory cytokine elevation after commencement of PD-1 inhibitors to predict efficacy in patients with non-small cell lung cancer
    Yuichi Ozawa, Yusuke Amano, Kei Kanata, Hasegwa Hirotsugu, Takashi Matsui, Takuya Kakutani, Takafumi Koyauchi, Masayuki Tanahashi, Hiroshi Niwa, Koshi Yokomura et al. · 2019 · Medical Oncology
69. The effect and safety of immune checkpoint inhibitor rechallenge in non-small cell lung cancer
    Hiromi Watanabe, Toshio Kubo, Kiichiro Ninomiya, Kenichiro Kudo, Daisuke Minami, Etsuko Murakami, Nobuaki Ochi, Takashi Ninomiya, Daijiro Harada, Masayuki Yasugi et al. · 2019 · Japanese Journal of Clinical Oncology
70. Anti-VEGF/VEGFR2 Monoclonal Antibodies and their Combinations with PD-1/PD-L1 Inhibitors in Clinic
    Feng Gao, Chun Yang · 2019 · Current Cancer Drug Targets
71. Association between CD47 expression, clinical characteristics and prognosis in patients with advanced non‐small cell lung cancer
    Oscar G. Arrieta, Alejandro Avilés‐Salas, Mario Orozco‐Morales, Norma Hernández‐Pedro, Andrés Felipe Cardona, Luis Antonio Cabrera-Miranda, Pedro Barrios‐Bernal, Giovanny Soca‐Chafre, Graciela Cruz‐Rico, María de Lourdes Peña-Torres et al. · 2020 · Cancer Medicine
72. Oligoprogressive Non-Small-Cell Lung Cancer under Treatment with PD-(L)1 Inhibitors
    Stephan Rheinheimer, Claus Peter Heußel, Philipp Mayer, Lena Gaissmaier, Farastuk Bozorgmehr, Hauke Winter, Felix J.F. Herth, Thomas Muley, Stephan Liersch, Helge G. Bischoff et al. · 2020 · Cancers
73. Comparing nanoparticle polymeric micellar paclitaxel and solvent-based paclitaxel as first-line treatment of advanced non-small-cell lung cancer: an open-label, randomized, multicenter, phase III trial
    Meiqi Shi, A. Gu, Hai‐Yan Tu, Cheng Huang, Huili Wang, Zhuang Yu, Xian‐qiang Wang, L. Cao, Yongqian Shu, H. Wang et al. · 2020 · Annals of Oncology
74. The progress and challenge of anti-PD-1/PD-L1 immunotherapy in treating non-small cell lung cancer
    Jingjing Qu, Quanhui Mei, Li Liu, Tianli Cheng, Peng Wang, Lijun Chen, Jianying Zhou · 2021 · Therapeutic Advances in Medical Oncology
75. Epigenetic regulation in lung cancer
    Shahin Ramazi, Maedeh Dadzadi, Zahra Sahafnejad, Abdollah Allahverdi · 2023 · MedComm
76. Neutrophil–lymphocyte ratio (NLR) predicted prognosis for advanced non-small-cell lung cancer (NSCLC) patients who received immune checkpoint blockade (ICB)
    Fangping Ren, Tian Zhao, Bing Liu, Lei Pan · 2019 · OncoTargets and Therapy
77. Predictors for Clinical Benefit of Immune Checkpoint Inhibitors in Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis
    Hazem Edmond El-Osta, Syed Hasan Raza Jafri · 2019 · Immunotherapy
78. Antitumor activity of an engineered decoy receptor targeting CLCF1–CNTFR signaling in lung adenocarcinoma
    Jun W. Kim, César P. Márquez, Kaja Kostyrko, Amanda L. Koehne, Kieren D. Marini, David R. Simpson, Alex Gia Lee, Stanley G. Leung, Leanne C. Sayles, Joseph B. Shrager et al. · 2019 · Nature Medicine
79. Local tumor microbial signatures and response to checkpoint blockade in non-small cell lung cancer
    Maximilian Boesch, Florent Baty, Werner C. Albrich, Lukas Flatz, Regulo Rodriguez, Sacha I. Rothschild, Markus Joerger, Martin Früh, Martin Hugo Brutsche · 2021 · OncoImmunology
80. Tumor Immune Microenvironment and Immunotherapy in Brain Metastasis From Non-Small Cell Lung Cancer
    Yu-Chang Wang, Rui Chen, Yue Wa, Shikuan Ding, Yijian Yang, Junbo Liao, Lei Tong, Gelei Xiao · 2022 · Frontiers in Immunology
81. Non-Invasive Measurement Using Deep Learning Algorithm Based on Multi-Source Features Fusion to Predict PD-L1 Expression and Survival in NSCLC
    Chengdi Wang, Jiechao Ma, Jun Shao, Shu Zhang, Jingwei Li, Junpeng Yan, Zhehao Zhao, Chengyu Bai, Yizhou Yu, Weimin Li · 2022 · Frontiers in Immunology
82. NEPTUNE: Phase 3 Study of First-Line Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLC
    Gilberto de Castro, Naiyer A. Rizvi, Peter Schmid, Konstantinos Syrigos, Claudio Marcelo Martin, Nobuyuki Yamamoto, Ying Cheng, Vladimir Mikhailovich Moiseyenko, Yvonne Summers, Ihor O. Vynnychenko et al. · 2022 · Journal of Thoracic Oncology
83. Association Between Age and Survival Trends in Advanced Non–Small Cell Lung Cancer After Adoption of Immunotherapy
    Teja Voruganti, Pamela R. Soulos, Ronac Mamtani, Carolyn Jean Presley, Cary Philip Gross · 2023 · JAMA Oncology
84. Clinical utility of pembrolizumab in the management of advanced solid tumors: an evidence-based review on the emerging new data
    P. du Rusquec, Ombline de Calbiac, M. Robert, M. Campone, J. Frenel · 2019 · Cancer Management and Research
85. Immunogenic Cell Death and Elimination of Immunosuppressive Cells: A Double-Edged Sword of Chemotherapy
    Jean-David Fumet, Emeric Limagne, Marion Thibaudin, François Ghiringhelli · 2020 · Cancers
86. Targeting the PD-1/PD-L1 Axis for the Treatment of Non-Small-Cell Lung Cancer
    Daniel E. Meyers, Paul Bryan, Shantanu Otto Banerji, Don G. Morris · 2018 · Current Oncology
87. Variation of Programmed Death Ligand 1 Expression After Platinum-based Neoadjuvant Chemotherapy in Lung Cancer
    Lei Guo, Peng Song, Xuemin Xue, Changyuan Guo, Liankui Han, Qing Fang, Jianming Ying, Shugeng Gao, Wenbin Li · 2019 · Journal of Immunotherapy
88. Cost-effectiveness of Atezolizumab Combination Therapy for First-Line Treatment of Metastatic Nonsquamous Non–Small Cell Lung Cancer in the United States
    Steven D. Criss, Meghan J. Mooradian, Tina R. Watson, Justin F. Gainor, Kerry Lynn Reynolds, Chung Yin Kong · 2019 · JAMA Network Open
89. Immune Checkpoint Inhibitors and Cardiac Toxicity in Patients Treated for Non-Small Lung Cancer: A Review
    Grzegorz Sławiński, Anna Wrona, Alicja Dąbrowska-Kugacka, Grzegorz Raczak, Ewa Lewicka · 2020 · International Journal of Molecular Sciences
90. EZH2 as a new therapeutic target in brain tumors: Molecular landscape, therapeutic targeting and future prospects
    Mahshid Deldar Abad Paskeh, Atefeh Mehrabi, Mohammad Hossein Gholami, Amirhossein Zabolian, Ehsan Ranjbar, Hossein Saleki, Adnan Ranjbar, Mehrdad Hashemi, Yavuz Nuri Ertaş, Kiavash Hushmandi et al. · 2021 · Biomedicine & Pharmacotherapy
91. Safety and Activity of Immune Checkpoint Inhibitors in People Living With HIV and Cancer: A Real-World Report From the Cancer Therapy Using Checkpoint Inhibitors in People Living With HIV-International (CATCH-IT) Consortium
    Talal El Zarif, Amin H. Nassar, Elio Adib, Bailey Gleason Fitzgerald, Jiaming Huang, Tarek H. Mouhieddine, Paul G. Rubinstein, Taylor Kristian Nonato, Rana R. McKay, Mingjia Li et al. · 2023 · Journal of Clinical Oncology
92. A comprehensive single-cell breast tumor atlas defines epithelial and immune heterogeneity and interactions predicting anti-PD-1 therapy response
    Lily Xu, Kaitlyn Saunders, Shao-Po Huang, Hildur Knútsdóttir, Kenneth Martinez-Algarin, Isabella Terrazas, Kenian Chen, Heather McArthur, Julia Maués, Christine Hodgdon et al. · 2024 · Cell Reports Medicine
93. Selective KRAS G12C inhibitors in non-small cell lung cancer: chemistry, concurrent pathway alterations, and clinical outcomes
    Palma, Gabriela, Khurshid, Faisal, Lu, Kevin, Woodward, Brian, Husain, Hatim · 2021 · npj Precision Oncology
94. Nanoparticle albumin bound-paclitaxel for treatment of advanced non-small cell lung cancer: an evaluation of the clinical evidence
    Diego Adrianzen Herrera, Nadia Ashai, Roman Perez-Soler, Haiying Cheng · 2018 · Expert Opinion on Pharmacotherapy
95. Current Treatment Landscape of Nasopharyngeal Carcinoma and Potential Trials Evaluating the Value of Immunotherapy
    Quynh‐Thu Le, Alexander Dimitrios Colevas, Brian O’Sullivan, Anne W.M. Lee, Nancy Y. Lee, Brigette B.Y. Ma, Lillian L. Siu, John N. Waldron, Chwee Ming Lim, Nadeem Riaz et al. · 2019 · JNCI Journal of the National Cancer Institute
96. Immunotherapy in breast cancer
    Soley Bayraktar, Sameer Ahmad Batoo, Scott H. Okuno, Stefan Glück · 2019 · Journal of Carcinogenesis
97. Immunopathogenesis of Immune Checkpoint Inhibitor-Related Adverse Events: Roles of the Intestinal Microbiome and Th17 Cells
    Ronald Anderson, Annette J. Theron, Bernardo Leon Rapoport · 2019 · Frontiers in Immunology
98. Weekly paclitaxel plus bevacizumab versus docetaxel as second- or third-line treatment in advanced non-squamous non–small-cell lung cancer: Results of the IFCT-1103 ULTIMATE study
    Alexis Benjamin Cortot, Clarisse Audigier-Valette, Olivier Molinier, Sylvestre Le Moulec, Fabrice Barlési, Gérard Zalcman, Patrick Dumont, Damien Pouessel, Claire Poulet, Clara Fontaine-Delaruelle et al. · 2020 · European Journal of Cancer
99. The Immune Landscape of Human Primary Lung Tumors Is Th2 Skewed
    Astri Frafjord, Linn Buer, Clara Louise Hammarström, Henrik Aamodt, Per Reidar Woldbæk, Odd Terje Brustugun, Åslaug Helland, Inger Øynebråten, Alexandre Corthay · 2021 · Frontiers in Immunology
100. Neutrophil Extracellular Traps in Cancer Therapy Resistance
     Muhammad H. Shahzad, Lixuan Feng, Xin Su, Ariane Brassard, Iqraa Dhoparee‐Doomah, Lorenzo Edwin Ferri, Jonathan David Spicer, Jonathan Cools‐Lartigue · 2022 · Cancers